13F Portfolios

Spruce Street Capital LP: RELMADA THERAPEUTICS INC (RLMD): Quarterly 13F Position History

As of Q1 2026, Spruce Street Capital LP reported 6,262,114 shares of RELMADA THERAPEUTICS INC (RLMD), worth $43.0M and representing 10.3% of its 13F equity book. Quarter-over-quarter share count change: + 2,175,933 (+53.3%) . The position first appeared in Q4 2025 and has been disclosed across 2 13F-HR filings in Pactolio's tracked window.

Recent initiation: Spruce Street Capital LP first reported RLMD on the Q4 2025 filing — fewer than three quarters of history are available.

Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 2 quarter s

Quarter Shares QoQ Share Change Share Change (%) Market Value Weight Implied Price
Q1 2026 6,262,114 +2,175,933 +53.3% $43.0M 10.3% $6.9
Q4 2025 4,086,181 $19.7M 6.5% $4.8

Methodology & FAQ

How This Position History Is Sourced

Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.

When did Spruce Street Capital LP first disclose a RLMD position in 13F-HR filings?

Spruce Street Capital LP first reported RELMADA THERAPEUTICS INC (RLMD) on its 13F-HR filing for the period ending 2025-12-31 (Q4 2025). The position has appeared on 2 reported quarters within Pactolio's tracked window.

What was Spruce Street Capital LP's most recent quarter-over-quarter share-count change in RLMD?

Between Q4 2025 and Q1 2026, Spruce Street Capital LP added 2,175,933 shares of RLMD (+53.3%), bringing the total reported position to 6,262,114 shares at a market value of $43.0M.

Does the implied price-per-share represent Spruce Street Capital LP's cost basis in RLMD?

No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.